Circulating miRNA Biomarkers for Hepatocellular Carcinoma Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for hepatocellular carcinoma (HCC) are inadequate for early detection, as they rely on imaging and serum alpha-fetoprotein levels, which lack sensitivity and specificity, often leading to late-stage diagnoses when treatment options are limited.
Innovation Solution
The use of circulating microRNAs (miRNAs) such as miR-16, miR-195, and miR-199a in body fluid samples for diagnosis, prognosis, and monitoring the effectiveness of anti-cancer therapy, combined with conventional markers like AFP, AFP-L3%, and DCP, to improve detection and management of HCC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging and serum AFP levels are used for HCC diagnosis, then the diagnostic method is simple and widely available, but the sensitivity and specificity are insufficient leading to late-stage diagnosis
Solution Approach 1:
The patent combines circulating miRNA detection with conventional diagnostic markers (AFP, AFP-L3%, DCP) to create a composite diagnostic approach. This merging of molecular biomarkers with traditional serological and imaging methods achieves superior sensitivity and specificity (92.4% sensitivity, 78.5% specificity) while maintaining clinical feasibility through standardized qRT-PCR technology
2Loss of time
If circulating miRNA detection is used to improve HCC detection sensitivity, then early detection capability is enhanced, but the diagnostic procedure becomes more complex
Solution Approach 1:
The patent establishes predetermined cutoff values for circulating miRNA levels based on extensive validation studies comparing HCC patients with chronic liver disease controls. These pre-established thresholds (e.g., miR-16 ΔCt ≥ 6, miR-199a ΔCt ≥ 10) enable rapid clinical interpretation without requiring complex statistical analysis, facilitating early detection while simplifying the diagnostic workflow
Solution Approach 2:
The patent uses an internal control RNA (e.g., U6 small nuclear RNA) as an intermediary to normalize circulating miRNA measurements. This intermediary accounts for variations in RNA extraction efficiency and reverse transcription conditions, enabling reliable quantification across different samples and laboratories without requiring complex calibration procedures
3Measurement precision
If multiple miRNA species are measured for improved diagnostic accuracy, then the detection precision increases, but the measurement process becomes more complex
Solution Approach 1:
The patent identifies and validates specific circulating miRNA species (miR-16, miR-195, miR-199a) that are differentially expressed in HCC compared to chronic liver disease. By segmenting the diagnostic approach into distinct miRNA targets with established cutoff values, the patent achieves high diagnostic accuracy while maintaining manageable measurement complexity through specialized qRT-PCR assays
Data Source
AI summary
Provided herein are methods for the diagnosis, or management of liver diseases, e.g.. hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.